Lastly, there are ongoing clinical trials for CAR-T cell therapies in CRC that target MUC1 (phase I/IIstudyNCT02617134), CEA (phase I study NCT03682744 and NCT02349724), NKG2DL (phase I study NCT03310008), as well as EGFR for metastatic CRC (phase I study NCT03542799), HER2 (phase I/II study NCT02713984 and phase I study NCT03740256), and CD133 (phase I/II study NCT02541370) [150]. Here, MUC1 is linked to colorectal carcinoma.